Rx Update
March
2008
OxyContin Update
New Strengths to Market
OxyContin® (oxycodone extended-release) is a controlled-release opioid analgesic indicated for the
management of moderate to severe pain when continuous analgesia is needed for an extended period
of time. Marketed by Purdue Pharma L.P., OxyContin was previously offered in only 10mg, 20mg,
40mg and 80mg formulations. In January 2008, additional strengths of brand-name OxyContin
became available. These new strengths include 15mg, 30mg and 60mg formulations. The dosages of
OxyContin 60mg and 80mg are only indicated for opioid-tolerant patients and should not be used for
initial opioid-naïve patients.
Generic Supplies Dwindling
On December 31, 2006, production of the generic formulation of oxycodone sustained-release was
halted due to patent infringement settlements between generic pharmaceutical companies and Purdue
Pharma L.P. Generic oxycodone sustained-release formulations were not required to be withdrawn
from the market and the supply has remained available, despite production termination from the generic
manufacturers.
More recently, sporadic supply issues with the generic product have started to appear. In response
to dwindling supplies, brand-name OxyContin has switched classification status in the national drug
database system from a “brand-with-a-generic-alternative” drug to a “single-source-brand” drug as of
early February 2008. This means that members will not incur a copayment penalty when requesting
brand-name OxyContin for prescription plans with a mandatory generic plan, and brand claims will
adjudicate according to the formulary status of OxyContin (preferred brand copayment for clients on
the Catalyst Rx formularies). Pharmacies may also continue to dispense generic oxycodone sustainedrelease until supplies are exhausted. The patient will continue to incur a generic copayment for the
generic product.
It is anticipated that all supplies of the generic oxycodone sustained-release will soon be exhausted and
only the brand formulation of OxyContin will be available. As a result, the client cost for this product
will increase. Currently, the average ingredient cost for a one-month supply of a generic oxycodone
sustained-release prescription is $225. The current average branded OxyContin ingredient cost for a
one-month supply is $527.
As part of our pharmacy benefit management services, Catalyst Rx partners with clients, members,
physicians, and pharmacies to provide updates regarding industry news and changes to product
availability. Catalyst Rx will continue to carefully monitor this situation and provide updates as
appropriate. If you have questions, please call the Catalyst Rx Clinical Department at 702-869-4900 or
the Catalyst Rx Customer Service Department at 1-800-997-3784.
1-888-869-4600 • 1-800-997-3784